Abstract
Novartis AG will report quarterly results on July 21, 2026, Pre-Market, with investor attention centered on revenue, margins, and adjusted EPS guidance alongside updates on portfolio and pipeline catalysts that have shaped expectations since January 2026.Market Forecast
The current quarter’s consensus points to revenue of 13.78 billion US dollars, implying a year-over-year decrease of 2.14%, with adjusted EPS forecast at 2.15, down 8.81% year over year; EBIT is projected at 11.31 billion US dollars, reflecting a 101.25% year-over-year increase. Formal guidance for gross margin and net margin has not been indicated for this quarter, but the prior quarter’s benchmarks were a gross profit margin of 74.58% and a net profit margin of 23.34%, which investors may use as reference points when assessing operating leverage.The company’s main business remained balanced by large-scale franchises last quarter: Oncology contributed 4.02 billion US dollars, Established Brands 3.29 billion US dollars, Immunology 2.47 billion US dollars, Cardiovascular, Renal and Metabolism 1.77 billion US dollars, and Neuroscience 1.56 billion US dollars. Within these, Oncology is positioned to carry the most visible near-term momentum given ongoing label and geographic expansion in targeted therapies and radioligand treatments; last quarter’s Oncology revenue was 4.02 billion US dollars, with qualitative catalysts in place this quarter to support continued demand.
Last Quarter Review
In the previous quarter, Novartis AG delivered revenue of 13.11 billion US dollars (down 0.91% year over year), a gross profit margin of 74.58%, GAAP net profit attributable to the parent company of 3.16 billion US dollars with a net profit margin of 23.34%, and adjusted EPS of 1.99 (down 12.72% year over year). A key financial highlight was a quarter-on-quarter improvement in net profit of 31.01%, reflecting tighter cost control and product mix resilience. In terms of main business highlights, Oncology led with 4.02 billion US dollars, while Immunology reached 2.47 billion US dollars and Established Brands 3.29 billion US dollars; overall group revenue declined 0.91% year over year, implying stable demand across key franchises despite product-specific competitive dynamics.Current Quarter Outlook
Core Portfolio Outlook
Consensus anticipates 13.78 billion US dollars of revenue, down 2.14% year over year, and adjusted EPS of 2.15, down 8.81%, indicating a cautious top line alongside pressure on per-share profitability as the company invests behind launches and pipeline integration. In the core portfolio, a mix of established blockbusters and newer specialty medicines continues to define the revenue base. The prior quarter’s gross margin at 74.58% and net margin at 23.34% set a high-quality benchmark; if product mix remains favorable and manufacturing efficiency holds, margins could remain broadly resilient even if net sales are slightly lower than the prior year.The largest revenue streams last quarter were Oncology at 4.02 billion US dollars and Established Brands at 3.29 billion US dollars, with Immunology at 2.47 billion US dollars providing breadth across autoimmune and inflammatory indications. This quarter, the cadence of demand in these franchises will be closely watched in light of competitive activity affecting established therapies and the need to support new indications. Investors will monitor whether operating expense growth tied to launches and business development is offset by incremental gross profit from higher-value therapies. Given that EBIT is projected to rise 101.25% year over year on consensus, markets appear to be baking in a step-up in operating leverage versus the comparable period, which would be notable if achieved alongside a modest revenue decline.
High-Potential Assets and Pipeline Catalysts
Oncology looks set to remain the most promising growth vector in the near term. The franchise delivered 4.02 billion US dollars last quarter, and the company has added to future growth options through external innovation and regulatory milestones during the current year. Notably, the announced agreement to acquire Myricx Bio for up to 1.50 billion US dollars, including 1.10 billion US dollars upfront and up to 0.40 billion US dollars in milestones, underscores a continued build-out in antibody-drug conjugates that can complement existing targeted oncology therapies. This move adds scientific breadth to the pipeline and provides additional shots on goal for post-2026 growth, though contributions to current-quarter revenue will be minimal.Pipeline execution also produced important readouts and approvals in 2026 that reinforce medium-term revenue visibility. Early-to-mid stage data for del-brax met key endpoints in facioscapulohumeral muscular dystrophy, adding optionality in neuromuscular disorders and signaling a broader expansion beyond traditional small molecules and biologics within the innovative medicines framework. In parallel, regulatory progress included European approval for a gene replacement therapy in spinal muscular atrophy for patients aged two and older, which adds another durable, high-value asset to the rare disease portfolio and supports pricing power and margin defense. While these achievements are unlikely to materially change this quarter’s revenue, they help frame expectations for accelerating launch revenues over the next several quarters and may influence management’s commentary on the ramp and manufacturing readiness.
The company also executed additional business development steps, including an oncology-focused collaboration valued up to 1.90 billion US dollars, that deepen the innovative pipeline and provide a path to sustain the core Oncology and Neuroscience contributions. For the current quarter, investors will scrutinize the degree to which these pipeline milestones translate into near-term commercial traction and how fast manufacturing capacity can scale to support potential demand inflections in oncology radioligands and gene therapies.
Stock Price Drivers and What to Watch This Quarter
Three factors appear most likely to shape the stock’s near-term reaction around the print. First, revenue quality and mix will be pivotal: if Oncology and other specialty medicines maintain share and price integrity, the company can protect its 70%+ gross margin profile despite a slight year-over-year revenue decline, which should support consensus EPS even as per-share comparisons are more challenging. The extent to which established therapies face competition from lower-cost alternatives will also be watched, since any incremental erosion there would require offsetting gains from newer launches to keep the top line near consensus.Second, operating leverage will be a focal point given the sharp step-up embedded in the EBIT forecast, which presumes both disciplined expense control and favorable product mix. A positive surprise on EBIT would signal that investments in launches and business development are being absorbed efficiently, while an in-line or weaker print could prompt investors to question the trajectory into the second half. The previous quarter’s 31.01% quarter-on-quarter increase in net profit provides a constructive baseline, but replication depends on both cost execution and the absence of unexpected spending spikes tied to integration and ramp activities.
Third, pipeline communication and business development updates should influence sentiment. The pending integration of recently announced acquisitions and collaborations, together with regulatory and clinical updates in oncology and rare disease programs, can reshape medium-term revenue expectations even if their short-term impact on sales is modest. Clear guidance on launch cadence, geographic rollout, and capacity scaling for complex modalities will help investors calibrate how quickly high-potential assets can contribute to the P&L. Management’s reiteration or refinement of full-year targets will also be important, particularly in light of earlier commentary indicating net sales growth in the low single-digits and a low single-digit decline in core operating income for 2026; any adjustment relative to that framing would likely move the stock.
Analyst Opinions
Across recent published views between January and mid-July 2026, the majority stance is bullish. Among the most visible opinions, two prominent institutions are positive while one update frames near-term profitability cautiously and one is neutral. On balance, this yields a clear tilt toward the bullish side of the ledger, with supportive arguments tied to portfolio durability, pipeline optionality, and operational execution.Morgan Stanley reaffirmed a Buy rating with a 170.00 US dollars price target, emphasizing confidence in the company’s ability to convert pipeline depth into commercial assets and to preserve attractive margins through effective launch sequencing. The firm’s constructive view aligns with the consensus EBIT forecast that implies markedly higher operating income year over year in the current quarter, a signal that markets expect prudent expense management and beneficial mix. Morgan Stanley’s stance effectively frames the upcoming report as an execution checkpoint: delivering on or near the implied operating leverage would validate the trajectory they see for the rest of 2026.
Argus Research also maintained a Buy rating with a 160.00 US dollars price target, focusing on the combination of established cash-generative therapies and late-stage innovation to support both near-term and multi-year earnings visibility. Their perspective highlights how clinical progress and targeted acquisitions in oncology and neuromuscular disease can fill portfolio gaps created by competitive pressure on certain mature brands. Argus’s view dovetails with the ongoing strategic emphasis on radioligand and gene-based therapies and suggests that investors should weigh the long-duration value of these platforms when interpreting any soft patches in quarterly revenue.
While one widely circulated note earlier this year underscored the possibility of a low single-digit decline in 2026 operating profit due to competition facing certain established medicines, the majority of analyst commentary over the last six months focuses on the company’s ability to offset pressures through innovation and business development. The neutral reiteration of full-year 2026 guidance—net sales growth in the low single-digits paired with a low single-digit decline in core operating income—serves as a realistic baseline against which upcoming quarterly performance will be judged. From a sentiment perspective, this backdrop sets the bar neither too high nor too low, giving room for upside if operating leverage materializes as consensus suggests.
In synthesizing these views, the bullish camp argues that the current-quarter forecast of 13.78 billion US dollars in revenue and 2.15 adjusted EPS is achievable, and that a stronger-than-expected EBIT could act as the primary positive surprise. They further point to this year’s pipeline and deal announcements—such as the agreement to acquire Myricx Bio—to support a sustained reinvestment cycle in high-value modalities that can structurally improve growth and margin profiles beyond 2026. The majority opinion thus anticipates a report that either meets or slightly exceeds the top-line and operating expectations while reinforcing medium-term confidence through pipeline updates and disciplined spending. If management’s commentary confirms steady demand in Oncology and reiterates the visibility of recent approvals and late-stage assets, the bullish case expects the shares to respond favorably, particularly given the balanced setup that includes cautious headline growth but improving operating efficiency.
Comments